JFG
VIR icon

Jefferies Financial Group’s Vir Biotechnology VIR Stock Holding History

Jefferies Financial Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,085,210
Closed -$8.13M – 1877
2024
Q3 		$8.13M Buy
+1,085,210
New +$9.43M 0.06% 213
2023
Q2 		– Sell
-60,500
Closed -$1.41M – 2032
2023
Q1 		$1.41M Buy
+60,500
New +$1.55M 0.01% 768

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Jefferies Financial Group's VIR Position: Q4 2024 in Review

Jefferies Financial Group sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 1,085,210 shares — an estimated $8.13M sold.

Jefferies Financial Group first reported a position in VIR in Q1 2023 and held it in 2 quarters. The position peaked at $8.13M in Q3 2024. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

  • Jefferies Financial Group reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 1,085,210 Vir Biotechnology shares in Q4 2024, an estimated $8.13M.
  • Jefferies Financial Group first reported a position in Vir Biotechnology in Q1 2023 and held it in 2 quarters.
  • Jefferies Financial Group's Vir Biotechnology position peaked at $8.13M in Q3 2024.
  • 208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on Jefferies Financial Group's 13F filing for Q4 2024, filed 14 Feb 2025.